CTI BioPharma was founded in 1992 and is headquartered in Seattle, US

CTI BioPharma has an office in Seattle

Seattle, US (HQ)

600 3101 Western Ave

## Revenue (2016) | $57.4 m |

## Revenue growth (2015-16), % | 256% |

## Net income (2016) | ($53 m) |

## Market capitalization (21-Mar-2017) | $120.3 m |

## Closing share price (21-Mar-2017) | $4.2 |

## Cash (31-Dec-2016) | $44 m |

CTI BioPharma's current market capitalization is $120.3 m.

CTI BioPharma's revenue was reported to be $57.4 m in FY, 2016 which is a **256.2% increase** from the previous period.

FY, 2010^{} | FY, 2011^{} | FY, 2012^{} | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} | |
---|---|---|---|---|---|---|---|

## Revenue | $319 k | $34.7 m | $60.1 m | $16.1 m | $57.4 m | ||

## Revenue growth, % | 73% | (73%) | 256% | ||||

## Cost of goods sold | $137 k | $895 k | $1.9 m | ||||

## Gross profit | $34.5 m | $59.2 m | $14.2 m | ||||

## Gross profit Margin, % | 100% | 99% | 88% | ||||

## Operating expense total | $76.1 m | $146.3 m | $130.8 m | ||||

## EBIT | ($41.5 m) | ($86.2 m) | ($116.7 m) | ($49.2 m) | |||

## EBIT margin, % | (120%) | (144%) | (724%) | (86%) | |||

## Interest expense | $2.2 m | $870 k | $56 k | $1 m | $1.9 m | $2.1 m | $2.6 m |

## Net Income | ($43.6 m) | ($94.2 m) | ($120.8 m) | ($53 m) |

Y, 2009^{} | Y, 2010^{} | Y, 2011^{} | Y, 2012^{} | Y, 2013^{} | Y, 2014^{} | Y, 2015^{} | FY, 2016^{} | |
---|---|---|---|---|---|---|---|---|

## Cash | $37.8 m | $22.6 m | $47.1 m | $50.4 m | $71.6 m | $70.9 m | $128.2 m | $44 m |

## Accounts Receivable | $235 k | $2 m | $282 k | $378 k | ||||

## Inventories | $3.6 m | $3.4 m | $3.7 m | $2.1 m | ||||

## Current Assets | $80.5 m | $80.5 m | $135 m | $55.8 m | ||||

## PP&E | $5.5 m | $4.6 m | $3.7 m | $3 m | ||||

## Total Assets | $93.7 m | $92.3 m | $144.3 m | $63.8 m | ||||

## Accounts Payable | $5.1 m | $6.4 m | $10.6 m | $7.2 m | ||||

## Current Liabilities | $20.1 m | $36.3 m | $72.4 m | $40.6 m | ||||

## Retained Earnings | ($1.9 b) | ($2 b) | ($2.1 b) | ($2.2 b) | ||||

## Total Equity | $42.8 m | $38.5 m | $47.4 m | $7.8 m | ||||

## Financial Leverage | 2.2 x | 2.4 x | 3 x | 8.2 x |

FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} | |
---|---|---|---|---|

## Net Income | ($43.6 m) | ($94.2 m) | ($120.8 m) | ($53 m) |

## Depreciation and Amortization | $1.6 m | $1.1 m | $990 k | $831 k |

## Accounts Receivable | ($227 k) | ($2 m) | $1.6 m | ($156 k) |

## Inventories | $4.5 m | $46 k | ($402 k) | $1.6 m |

## Accounts Payable | ($5.8 m) | $1.5 m | $4.4 m | ($3 m) |

## Cash From Operating Activities | ($35.8 m) | ($39.6 m) | ($95.2 m) | ($76.7 m) |

## Purchases of PP&E | ($1.7 m) | ($333 k) | ($78 k) | ($137 k) |

## Cash From Investing Activities | ($1.5 m) | ($541 k) | ($78 k) | ($137 k) |

## Long-term Borrowings | ($1.5 m) | |||

## Interest Paid | $933 k | $1.9 m | $2.1 m | $4.4 m |

## Income Taxes Paid |